Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients

dc.citation.issue1
dc.citation.spage162-167
dc.citation.volume201
dc.contributor.authorDjebbari, F.
dc.contributor.authorRampotas, A.
dc.contributor.authorVallance, G.
dc.contributor.authorPanitsas, F.
dc.contributor.authorBasker, N.
dc.contributor.authorSangha, G.
dc.contributor.authorSalhan, B.
dc.contributor.authorKarim, F.
dc.contributor.authorAl-Kaisi, F.
dc.contributor.authorGudger, A.
dc.contributor.authorNgu, L.
dc.contributor.authorPoynton, M.
dc.contributor.authorLam, H. P. J.
dc.contributor.authorMorgan, L.
dc.contributor.authorYang, L.
dc.contributor.authorYoung, J.
dc.contributor.authorWalker, M.
dc.contributor.authorTsagkaraki, I.
dc.contributor.authorAnderson, L.
dc.contributor.authorChauhan, S. R.
dc.contributor.authorMaddams, R.
dc.contributor.authorSoutar, R.
dc.contributor.authorTriantafillou, M.
dc.contributor.authorPrideaux, S.
dc.contributor.authorObeidalla, A.
dc.contributor.authorEyre, T. A.
dc.contributor.authorBygrave, C.
dc.contributor.authorKothari, J.
dc.contributor.authorBasu, S.
dc.contributor.authorRamasamy, K.
dc.date.accessioned2023-07-14T13:25:06Z
dc.date.available2023-07-14T13:25:06Z
dc.date.epub2023-02-01
dc.date.issued2023-04-01
dc.description.admin-notePublished version, accepted version (12 month embargo), submitted version
dc.description.noteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
dc.identifier.citationBr J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31.
dc.identifier.doi10.1111/bjh.18672
dc.identifier.journalBritish journal of haematology
dc.identifier.pmid36720464
dc.identifier.urihttps://hdl.handle.net/11287/622882
dc.language.isoeng
dc.publisherWiley
dc.relation.urlhttps://doi.org/10.1111/bjh.18672
dc.rights© 2023 British Society for Haematology and John Wiley & Sons Ltd.
dc.subjectHumans
dc.subject*Multiple Myeloma/drug therapy
dc.subject*Frailty
dc.subjectDexamethasone/therapeutic use
dc.subjectUnited Kingdom/epidemiology
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic use
dc.subjectNeoplasm Recurrence, Local/drug therapy
dc.subjectfrailty
dc.subjectisatuximab
dc.subjectmyeloma
dc.subjectpomalidomide
dc.subjectreal-world
dc.titleFrailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients
dc.typeLetter
dc.type.versionppublish
Files